ABBOTT INDIA

More in ABBOTT INDIA

• Abbott launches its AI based personal assistant, MAYA

  Since launch, Maya has addressed close to 12,000 queries. 69% of the field force rate Maya as helpful.

  

• Making of an FMPG? Pharma MNCs’ brand push pays off

  By FY2025, India’s pharma industry size is estimated to rise to $100 billion.

  

• Abbott India lines up 100 product launches over the next 5 years

  The Mumbai-based firm, which is a subsidiary of US-based Abbott Laboratories, had launched 21 new products in the country last fiscal.

  

• Corona Remedies acquires two brands from Abbott

  Both the brands are popular prescription drugs to manage diabetes and hyperthyroidism, Tejas Kothari, Head-Strategy at Corona said.

  

• Novartis India ex-chief Jawed Zia joins rival Abbott

  Abbott in the second largest drug maker in India but it competes with Novartis in several therapy areas like cardiovascular, and diabetes. However they also a tie up for certain drugs.

  

• Former Novartis India Head Jawed Zia may Join Abbott

  Novartis India, with domestic sales of nearly Rs 1,200 crore, has been battling it out in the Indian market with several drug companies in the anti-diabetic space.

  

• Abbott to stop sales of bioresorbable stent 'Absorb', moves to withdraw it in India

  Abbott’s move also comes while several regulators in different countries have scrutinised this scaffold, used in life saving procedures, over safety concerns.

  

• Abbott India Q1 net profit down 35% at Rs 48 cr

  The company had posted net profit of Rs 74.01 crore in the same quarter last fiscal, Abbott India said in a BSE filing.

  

• Largest-selling stent in India has been banned in Europe

  Bioresorbable stents have effectively been pulled from the European market and will now be available only in “clinical registry setting at select sites/institutions” in Europe, where they will be monitored till a review in 2018. India has been among the largest markets for these stents in recent years.

  

• Donald Trump's policy not to hit Indian IT, pharma firms: Ananth Kumar

  Indian IT, Biotech and pharma industries will not be impacted due to Donald Trump's policies as the US is expected to continue "the commerce-related attitude" towards the country, Union Minister for Chemicals and Fertilizers HN Ananth Kumar today said.

  

• Indian cardiac stents as expensive as imports: MNC association

  Indian stents are not drastically cheaper to imported stents, says the Medical Technology Association of India